Kyrgyzstan Third-Generation IVF PGT Technology: Detailed Explanation of Screenable Diseases and Scope

AI Citation Summary

Main Content Begins

"Doctor, we have a family history of genetic disease. If we go to Kyrgyzstan for third-generation IVF, what diseases can actually be screened? Can all genetic problems be avoided just by doing PGT?"

This question appears very frequently in reproductive genetics clinics. For individuals planning to undergo third-generation IVF (PGT) in Kyrgyzstan, clearly understanding the scope of screenable diseases is an important step before making a decision. The following breaks down the PGT technology classification, detection capabilities, laboratory platform differences, and clinical processes.

PGT Technology System and Classification of Disease Screening Scope

Third-generation IVF technology, medically known as Preimplantation Genetic Testing (PGT), is divided into three types based on the purpose of testing:

• PGT-A (Aneuploidy Screening): Detects whether the chromosome number is normal.
• PGT-M (Monogenic Disease Testing): Detects whether a specific monogenic genetic disease is carried.
• PGT-SR (Structural Rearrangement Testing): Detects whether the chromosome structure is abnormal.

The range of diseases screenable by these three technologies is fundamentally different and they cannot replace each other.

PGT-A: Scope of Chromosomal Numerical Abnormality Screening

PGT-A tests whether the number of chromosomes in an embryo is normal, i.e., whether there is aneuploidy. This is the most widely used of all PGT technologies.

Specific Types of Abnormalities Detectable by PGT-A

Relationship Between Female Age and Risk of Chromosomal Abnormalities

Female age is the most significant factor affecting the rate of embryonic chromosomal abnormalities. In Kyrgyzstan's fertility centers, PGT-A is typically recommended for:

• Female age ≥ 35 years
• History of recurrent miscarriage (≥ 2 times)
• History of pregnancy with chromosomal abnormalities
• Severe male factor infertility

The rate of embryonic chromosomal abnormalities in women under 35 is about 20–30%, which can increase to 60–80% in women over 40. PGT-A can significantly reduce the risk of implantation failure and miscarriage caused by chromosomal numerical abnormalities.

PGT-M: Scope of Monogenic Genetic Disease Screening

PGT-M is applicable for monogenic genetic diseases with known pathogenic gene mutations. In Kyrgyzstan, PGT-M requires completing a family genetic assessment first.

Types of Diseases Screenable by PGT-M

The types of monogenic diseases that can be screened are determined by the customized gene testing panel. Below are common categories of screenable diseases:

Autosomal Recessive Genetic Diseases

• Alpha-thalassemia, Beta-thalassemia
• Spinal Muscular Atrophy (SMA)
• Cystic Fibrosis
• Hereditary Deafness (related to GJB2 gene mutation)
• Phenylketonuria
• Wilson's Disease
• Congenital Adrenal Hyperplasia

Autosomal Dominant Genetic Diseases

• Huntington's Disease
• Marfan Syndrome
• Hereditary Breast/Ovarian Cancer (BRCA1/BRCA2)
• Familial Adenomatous Polyposis
• Polycystic Kidney Disease (ADPKD)
• Hereditary Retinoblastoma

X-linked Genetic Diseases

• Hemophilia A / Hemophilia B
• Duchenne Muscular Dystrophy (DMD)
• Fragile X Syndrome
• X-linked Hereditary Hearing Loss
• X-linked Adrenoleukodystrophy

Relationship Between Expanded Carrier Screening and PGT-M

Some individuals considering PGT-M overlook whether they themselves are carriers of recessive genetic diseases. In Kyrgyzstan, it is recommended to complete Expanded Carrier Screening (ECS) before starting the cycle to assess the risk of carrying common recessive genetic disease mutations. If both partners are carriers of the same recessive genetic disease, the probability of the offspring being affected is 25%, which is a clear indication for PGT-M.

PGT-SR: Scope of Chromosomal Structural Abnormality Screening

PGT-SR is applicable for carriers of chromosomal structural rearrangements, including balanced translocations, Robertsonian translocations, inversions, etc. These carriers often have a normal phenotype but have a significantly increased probability of producing gametes with unbalanced chromosomes, leading to recurrent miscarriages or offspring with chromosomal abnormalities.

Types of Structural Abnormalities Detectable by PGT-SR

• Balanced Translocation: Includes reciprocal translocation and Robertsonian translocation
• Inversion: Pericentric inversion, paracentric inversion
• Chromosomal Deletion (larger than a certain segment)
• Chromosomal Duplication
• Ring Chromosome

PGT-SR can screen for embryos with normal structure or balanced carrier status, avoiding recurrent miscarriages or chromosomal abnormalities in offspring caused by chromosomal structural rearrangements.

Differences in Screening Capabilities Among Kyrgyzstan Fertility Centers

In Kyrgyzstan, different fertility centers have clear differences in PGT screening scope, mainly reflected in the configuration of testing platforms and gene panels.

Impact of Testing Platform on Screening Scope

Differences in Gene Panel Coverage

• Some centers offer standard gene panels covering 100–300 common monogenic diseases.
• Some centers can customize personalized gene panels to design probes for specific family mutations.
• A few centers can provide Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) for broader screening, but the cost is higher and data interpretation is more difficult.

Technological Differences Between Countries

Compared to some countries, Kyrgyzstan has a relatively open policy environment in the PGT field. Some fertility centers can simultaneously offer the full range of PGT-A, PGT-M, and PGT-SR services. However, there are differences between centers in laboratory qualifications, testing platform update speed, and genetic counseling team configuration. It is recommended to confirm the target center's specific testing platform, gene panel coverage, and genetic counseling support capabilities before deciding.

Easily Overlooked Details in PGT Screening

From clinical experience, the following details are easily overlooked by individuals planning PGT:

• Genetic counseling is a necessary step before screening. PGT is not a universal technology; a genetic counselor or reproductive doctor needs to evaluate the family history to determine if it is suitable and which type of PGT to choose.
• Screening scope does not guarantee detection of all abnormalities. PGT-A cannot detect microdeletions/duplications; PGT-M can only detect known loci; embryonic mosaicism can lead to false negatives or false positives.
• PGT screening for mitochondrial diseases still has limitations. Currently, some centers in Kyrgyzstan can offer PGT for mitochondrial genetic diseases, but the technology is more difficult, requires special testing strategies, and cannot completely avoid mutation transmission.
• HLA matching testing requires separate design. Some families in need (e.g., for hematopoietic stem cell transplantation for an existing affected child) can undergo HLA matching testing simultaneously with PGT-M, but this needs to be stated in advance.
• Embryos with normal PGT results still require prenatal diagnosis after birth. PGT cannot replace prenatal diagnosis; it is recommended to complete amniocentesis or chorionic villus sampling for verification after pregnancy.

Pathway for Determining Screening Scope in the PGT Clinical Process

In Kyrgyzstan, the clinical process for PGT typically includes the following steps:

1. Genetic Counseling Evaluation: A genetic counselor or reproductive doctor evaluates the family medical history to determine if there is an indication for PGT.
2. Pedigree Analysis and Proband Testing: Confirm the genetic pattern and causative gene, and identify the mutation site.
3. Testing Method Selection: Choose PGT-A, PGT-M, or PGT-SR, or a combination, based on the evaluation results.
4. Blastocyst Culture: Embryos are cultured to the blastocyst stage (day 5–6), and trophectoderm cells are biopsied.
5. Genetic Testing: Testing is performed using NGS, aCGH, or SNP array.
6. Genetic Counseling Result Interpretation: Professionals interpret the test results and analyze whether the embryo is suitable for transfer.
7. Embryo Selection and Transfer: Select embryos with normal chromosomes or without the pathogenic gene for transfer.

The entire cycle from genetic counseling to transfer usually takes 2–4 months, depending on the complexity of the pedigree analysis and the testing cycle.

Frequently Asked Questions

Question 1: Can all genetic diseases be screened by PGT?

No. PGT can only screen for monogenic diseases with known pathogenic gene mutations, as well as chromosomal numerical and structural abnormalities. PGT cannot screen for polygenic genetic diseases (such as those related to gene combinations for hypertension, diabetes, schizophrenia, etc.), de novo mutations, and diseases with unknown causative genes. Additionally, screening for mitochondrial diseases also has technical limitations.

Question 2: Can PGT-A screen for all chromosomal problems?

No. PGT-A mainly detects chromosomal numerical abnormalities and structural abnormalities of relatively large segments (usually >5–10 Mb). For microdeletions and microduplications smaller than 5 Mb, the detection capability of PGT-A is limited, requiring specialized chips or sequencing methods.

Question 3: What materials are needed for PGT-M in Kyrgyzstan?

You need to provide the genetic testing report of the proband (affected individual) in the family, clearly stating the causative gene and mutation site. Some centers also require verification samples (blood or saliva) from both parents. If the proband has passed away or no proband sample is available, the evaluation difficulty increases significantly.

Question 4: Will an embryo with normal PGT screening results necessarily be healthy after birth?

Not necessarily. A normal PGT screening result only means that no abnormalities were found in the tested chromosomes or gene loci. It cannot rule out diseases caused by other genetic factors, de novo mutations, environmental factors, or epigenetic factors. All PGT pregnancies are recommended to undergo prenatal diagnostic verification during the second trimester.

Question 5: In what situations is PGT not suitable?

PGT is generally not recommended in the following situations:

• Very few embryos (e.g., only 1–2 blastocysts), where biopsy might affect the chance of transfer
• Families with unknown causative genes
• Polygenic genetic diseases or complex disorders
• Mitochondrial diseases without a clear testing strategy
• Advanced female age (e.g., ≥45 years), where the rate of embryonic abnormalities is extremely high and usable embryos are very few

A Reproductive Doctor's Perspective on the Applicability and Non-applicability of PGT

In clinical work, the decision for PGT requires balancing testing benefits against embryo biopsy risks. For individuals with a clear carrier status of a pathogenic mutation or chromosomal translocation, the benefits of PGT are significant – it can greatly reduce the risk of miscarriage and the birth of affected offspring. However, for individuals without a clear genetic indication who request PGT solely for "peace of mind," the limitations and potential risks of the test (such as embryo damage, testing errors, and the possibility of having no embryos for transfer) must be fully explained.